Related Experiment Video

Updated: Jun 28, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.5K

Guideline for diagnosis and management of congenital dysfibrinogenemia

Jie Yan1, Lin Liao2, Donghong Deng3

  • 1Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Key Laboratory of Clinical Laboratory Medicine of Guangxi, Department of Education, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|April 20, 2024
PubMed

Insights

Congenital dysfibrinogenemia (CD) diagnosis is improved with new criteria combining Clauss and PT methods. Comprehensive treatment strategies are recommended based on individual patient bleeding or thrombosis risk.

Area of Science:

  • Hematology
  • Clinical Diagnostics
  • Genetics

Background:

  • Congenital dysfibrinogenemia (CD) involves abnormal fibrinogen structure leading to coagulation dysfunction.
  • Clinical presentations range from asymptomatic to bleeding and thrombosis, with a high rate of asymptomatic cases.
  • Current single fibrinogen detection methods risk missed or incorrect diagnoses.

Purpose of the Study:

  • To propose a novel diagnostic criteria for congenital dysfibrinogenemia.
  • To summarize comprehensive treatment recommendations for CD patients.

Main Methods:

  • Developed a diagnostic criteria combining Clauss and PT-derived fibrinogen detection methods.
  • Integrated clinical manifestations, family history, and genetic testing into the diagnostic approach.
  • Synthesized treatment guidelines based on literature and existing recommendations.

Main Results:

  • The new criteria utilize fibrinogen detection ratios for CD diagnosis.
  • Diagnosis requires integration of clinical data, family history, and genetic testing.
  • Treatment strategies are tailored to individual patient manifestations (bleeding, thrombosis, asymptomatic).

Conclusions:

  • The new diagnostic criteria and treatment recommendations enhance CD management.
  • Effective diagnosis and personalized treatment are crucial for improving patient outcomes.
Abstract

Keywords:
Congenital dysfibrinogenemiaDiagnosisFibrinogenManagement

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.8K

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
157
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
158
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
Flail Chest-II01:26

Flail Chest-II

Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
168
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60